Renal cell carcinoma adjuvant therapy following nephrectomy

Renal cell carcinoma adjuvant therapy following nephrectomy refers to the postoperative administration of systemic treatment to reduce the risk of disease recurrence or death in patients with kidney cancer who have undergone curative-intent surgical resection In this clinical state, adjuvant systemic therapy targets subclinical residual tumor burden within the host tissue to prolong disease-free and overall survival

Renal cell carcinoma adjuvant therapy following nephrectomy refers to the postoperative administration of systemic treatment to reduce the risk of disease recurrence or death in patients with kidney cancer who have undergone curative-intent surgical resection Following radical or partial nephrectomy, patients categorized as intermediate-high or high risk for relapse—defined by features such as advanced tumor stage, high nuclear grade, lymph node involvement, sarcomatoid differentiation, or compl...

Renal cell carcinoma arises from the tubular epithelium of the renal parenchyma and predominantly affects adult populations In this clinical state, adjuvant systemic therapy targets subclinical residual tumor burden within the host tissue to prolong disease-free and overall survival

Renal cell carcinoma arises from the tubular epithelium of the renal parenchyma and predominantly affects adult populations

Following radical or partial nephrectomy, patients categorized as intermediate-high or high risk for relapse—defined by features such as advanced tumor stage, high nuclear grade, lymph node involvement, sarcomatoid differentiation, or completely resected oligometastatic lesions—exhibit a substantial propensity for occult micrometastatic disease despite complete macroscopic removal

Following radical or partial nephrectomy, patients categorized as intermediate-high or high risk for relapse—defined by features such as advanced tumor stage, high nuclear grade, lymph node involvement, sarcomatoid differentiation, or completely resected oligometastatic lesions—exhibit a substantial propensity for occult micrometastatic disease despite complete macroscopic removal

In this clinical state, adjuvant systemic therapy targets subclinical residual tumor burden within the host tissue to prolong disease-free and overall survival